A study revealed that IBD patients, particularly those with ulcerative colitis and multiple biologic treatments, face an ...

Opening up can unlock much-needed support, but it also comes with risks. The flare-up started like all of the others: intense ...

Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

Bloating is a common digestive issue affecting people of all ages, however, the experience becomes more frequent and severe ...

GUANGZHOU, China I 7, 2025 I Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...

The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are excited to host the annual Crohn’s & Colitis Congress®, taking place Feb. 6-8, in San Francisco, CA. This ...

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...

Collagenous colitis and lymphocytic colitis, the two main subtypes of microscopic colitis, may develop as a result of an immune response. This could happen when something causes the body to ...

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the large intestine, causing persistent inflammation in the colon and rectum. The condition typically begins in the ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease and ulcerative colitis, is the company's latest step into the treatment of ...

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad 382355, Gujarat, India Department of Pharmacology and Toxicology, College of ...